Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
January 22, 2018
Oil rises as Saudi Arabia says producers will cooperate beyond 2018
January 22, 2018

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases.

Powered by WPeMatico